Cimzia® - Ankylosing spondylitis (AS) Cimzia® (certolizumab pegol) is a tumor necrosis factor (TNF) blocker indicated in the US for the treatment of adults with active ankylosing spondylitis (AS).Warning: serious infections and malignancySee full prescribing information for complete boxed warning. Increased risk of serious infections leading to hospitalisation or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (5.1)Cimzia should be discontinued if a patient develops a serious infection or sepsis (5.1)Perform test for latent TB; if positive, start treatment for TB prior to starting Cimzia (5.1)Monitor all patients for active TB during treatment, even if initial latent TB test is negative (5.1)Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which Cimzia is a member (5.2). Cimzia is not indicated for use in pediatric patients (8.4). Prescribing information USA US prescribing information Related website Cimzia® product website (for US residents only)
